Epigenetic Therapeutics: A New Weapon in the War Against Cancer.

The past 15 years have seen an explosion of discoveries related to the cellular regulation of phenotypes through epigenetic mechanisms. This regulation provides a software that packages DNA, without changing the primary base sequence, to establish heritable patterns of gene expression. In cancer, many aspects of the epigenome, controlled by DNA methylation, chromatin, and nucleosome positioning, are altered as one means by which tumor cells maintain abnormal states of self-renewal at the expense of normal maturation. Epigenetic and genetic abnormalities thus collaborate in cancer initiation and progression, as exemplified by frequent mutations in genes encoding proteins that control the epigenome. There is growing emphasis on using epigenetic therapies to reprogram neoplastic cells toward a normal state. Many agents targeting epigenetic regulation are under development and entering clinical trials. This review highlights the promise that epigenetic therapy, often in combination with other therapies, will become a potent tool for cancer management over the next decade.

[1]  M. Beckmann,et al.  Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses , 2016 .

[2]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[3]  J. Qi,et al.  Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010-2014). , 2015, Pharmaceutical patent analyst.

[4]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[5]  Li Ma,et al.  The emerging molecular machinery and therapeutic targets of metastasis. , 2015, Trends in pharmacological sciences.

[6]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[7]  L. Maher,et al.  Oxygen Concentration Controls Epigenetic Effects in Models of Familial Paraganglioma , 2015, PloS one.

[8]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[9]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[10]  Richard L Schilsky,et al.  Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Wolchok,et al.  Genetic basis for clinical response to CTLA-4 blockade in melanoma. , 2014, The New England journal of medicine.

[12]  T. Bestor,et al.  Notes on the role of dynamic DNA methylation in mammalian development , 2014, Proceedings of the National Academy of Sciences.

[13]  M. Beksac,et al.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. , 2014, The Lancet. Oncology.

[14]  S. Grant,et al.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. , 2014, Pharmacology & therapeutics.

[15]  S. Baylin,et al.  The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes , 2014, Oncogene.

[16]  J. Herman,et al.  Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Solter,et al.  DNA methylation dynamics during epigenetic reprogramming in the germline and preimplantation embryos , 2014, Genes & development.

[18]  Gang Wu,et al.  Histone H3 mutations in pediatric brain tumors. , 2014, Cold Spring Harbor perspectives in biology.

[19]  E. Seto,et al.  Erasers of histone acetylation: the histone deacetylase enzymes. , 2014, Cold Spring Harbor perspectives in biology.

[20]  Peter A. Jones,et al.  Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers , 2014, Oncotarget.

[21]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[22]  S. Baylin,et al.  Harnessing the potential of epigenetic therapy to target solid tumors. , 2014, The Journal of clinical investigation.

[23]  M. Gilbert,et al.  Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Y. Schwartz,et al.  A new world of Polycombs: unexpected partnerships and emerging functions , 2013, Nature Reviews Genetics.

[25]  Peter A. Jones,et al.  Alterations of immune response of non-small cell lung cancer with Azacytidine , 2013, Oncotarget.

[26]  Pu Zhang,et al.  DNMT1-interacting RNAs block gene specific DNA methylation , 2013, Nature.

[27]  S. Sleiman,et al.  Epigenetics of Alzheimer’s Disease and Frontotemporal Dementia , 2013, Neurotherapeutics.

[28]  William A. Pastor,et al.  TETonic shift: biological roles of TET proteins in DNA demethylation and transcription , 2013, Nature Reviews Molecular Cell Biology.

[29]  Bohuslav Melichar,et al.  Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Zahnow,et al.  The future of epigenetic therapy in solid tumours—lessons from the past , 2013, Nature Reviews Clinical Oncology.

[31]  M. Millan An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy , 2013, Neuropharmacology.

[32]  Marco A. Marra,et al.  Cancer genome-sequencing study design , 2013, Nature Reviews Genetics.

[33]  J. Huse,et al.  Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. , 2013, Journal of neuropathology and experimental neurology.

[34]  Peter W. Laird,et al.  Interplay between the Cancer Genome and Epigenome , 2013, Cell.

[35]  E. Lander,et al.  Lessons from the Cancer Genome , 2013, Cell.

[36]  A. H. Smits,et al.  Dynamic Readers for 5-(Hydroxy)Methylcytosine and Its Oxidized Derivatives , 2013, Cell.

[37]  C. Roberts,et al.  ARID1A mutations in cancer: another epigenetic tumor suppressor? , 2013, Cancer discovery.

[38]  Jeannie T. Lee Epigenetic Regulation by Long Noncoding RNAs , 2012, Science.

[39]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[40]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[41]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[42]  Peter A. Jones,et al.  Cancer genetics and epigenetics: two sides of the same coin? , 2012, Cancer cell.

[43]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[44]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[45]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[46]  H. Hock A complex Polycomb issue: the two faces of EZH2 in cancer. , 2012, Genes & development.

[47]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[48]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[49]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[50]  M. Esteller,et al.  Cancer epigenomics: beyond genomics. , 2012, Current opinion in genetics & development.

[51]  Martin Renqiang Min,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[52]  J. Uhm IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012 .

[53]  F. Rassool,et al.  HDAC inhibitors: roles of DNA damage and repair. , 2012, Advances in cancer research.

[54]  J. Herman,et al.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. , 2011, Cancer discovery.

[55]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[56]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[57]  G. Mufti,et al.  Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes , 2011, Cancer.

[58]  R. Bast,et al.  Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer , 2011, Cancer.

[59]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[60]  Peter A. Jones,et al.  Epigenetic Modifications as Therapeutic Targets , 2010, Nature Biotechnology.

[61]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[62]  K. Helin,et al.  Polycomb group protein-mediated repression of transcription. , 2010, Trends in biochemical sciences.

[63]  R. Wilson,et al.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.

[64]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[65]  Peter A. Jones,et al.  S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth , 2010, Molecular Cancer Therapeutics.

[66]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[67]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[68]  C. Caskey Using genetic diagnosis to determine individual therapeutic utility. , 2010, Annual review of medicine.

[69]  M. Maitland,et al.  Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Kristian Helin,et al.  Polycomb group proteins: navigators of lineage pathways led astray in cancer , 2009, Nature Reviews Cancer.

[71]  M. Gobbi,et al.  Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes , 2009, Clinical Cancer Research.

[72]  A. Shilatifard,et al.  An operational definition of epigenetics. , 2009, Genes & development.

[73]  G. Garcia-Manero Demethylating agents in myeloid malignancies , 2008, Current opinion in oncology.

[74]  A. Feinberg,et al.  Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA , 2008, Nature.

[75]  T. Tomasi,et al.  Histone deacetylase regulation of immune gene expression in tumor cells , 2008, Immunologic research.

[76]  R. Schneider,et al.  Dynamics and interplay of nuclear architecture, genome organization, and gene expression. , 2007, Genes & development.

[77]  S. Berger The complex language of chromatin regulation during transcription , 2007, Nature.

[78]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[79]  J. Herman,et al.  Combined Methyltransferase/Histone Deacetylase Inhibition with 5-Azacitidine and MS-275 in Patients with MDS, CMMoL and AML: Clinical Response, Histone Acetylation and DNA Damage. , 2006 .

[80]  P. Pandolfi,et al.  Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome , 2006, Leukemia.

[81]  H. Clevers Wnt/beta-catenin signaling in development and disease. , 2006, Cell.

[82]  G. Mufti,et al.  Methylation inhibitor therapy in the treatment of myelodysplastic syndrome , 2005, Nature Clinical Practice Oncology.

[83]  J. Issa DNA methylation in the treatment of hematologic malignancies. , 2005, Clinical advances in hematology & oncology : H&O.

[84]  K. Ghoshal,et al.  5-Aza-Deoxycytidine Induces Selective Degradation of DNA Methyltransferase 1 by a Proteasomal Pathway That Requires the KEN Box, Bromo-Adjacent Homology Domain, and Nuclear Localization Signal , 2005, Molecular and Cellular Biology.

[85]  Richard Pazdur,et al.  FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. , 2005, The oncologist.

[86]  Wei Dong Chen,et al.  Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer , 2004, Nature Genetics.

[87]  David A Jones,et al.  Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. , 2004, Molecular pharmacology.

[88]  J. Holland,et al.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[89]  Keith D Robertson,et al.  DNA methylation, methyltransferases, and cancer , 2001, Oncogene.

[90]  M. Lübbert,et al.  DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. , 2000, Current topics in microbiology and immunology.

[91]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[92]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.

[93]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.